Press Releases

Reported €30.2 million in cash and cash equivalents as of March 31, 2023 PARIS and CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment

Company agreed to term sheet as of May 3, 2023  PARIS and CAMBRIDGE, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), today announced that the Company is entering into final contract negotiations after agreement to a non-binding term sheet for

Pivotal Phase 3 trial NANORAY-312 ongoing globally with 104 sites activated in 25 countries to date; interim efficacy analysis after 67% of planned progression free survival (PFS) events expected in H2 2024, as planned Final data from Study 102 in head and neck cancer expected in H2 2023 First

Conference Call and Webcast to be Held at 2:00 PM CEST/8:00 AM EDT on April 25, 2023 PARIS and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the “ Company ”), a late-stage clinical biotechnology company pioneering physics-based approaches to

PARIS, April 11, 2023 (GLOBE NEWSWIRE) -- In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) Paris, France, April 11, 2023 Market: Euronext Paris / Nasdaq Euronext

PARIS and CAMBRIDGE, Mass. , March 27, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the

Conference Call and Webcast to be Held at 2:00 P.M CET/ 8:00 A.M. EDT on March 29, 2023   PARIS and CAMBRIDGE, Mass. , March 14, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-stage clinical biotechnology company pioneering physics-based approaches

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) Name:DistributionId Value:8749207 --> Name:EnableQuoteCarouselOnPnr Value:False --> Name:IcbCode Value:4573 -->

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS , Jan. 11, 2023 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: